SCHEMBL4736844

SCHEMBL4736844

Nc1cc(Cl)c(C(=O)O)cc1I

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA3 P07451 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA13 Q8N1Q1 1/20 0.46
CISD1 Q9NZ45 1/20 0.46
CA14 Q9ULX7 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
CYP3A4 P08684 1/20 0.46
ALDH1A1 P00352 6/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
CASP1 P29466 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31515141 0.92 CA12 (0.46) CA12CA1CA2CA3CA4
SCHEMBL5550646 0.84 CYP3A4 (0.46) CA12CA1CA2CA3CA4
SCHEMBL3131937 0.83 CYP3A4 (0.52) CA12CA1CA2CA3CA4
SCHEMBL121510 0.82 GAA (0.36) CA1CA2CA9CYP3A4ALDH1A1
SCHEMBL31086529 0.81 KDM4E (0.43) CYP3A4ALDH1A1TP53CASP1KDM4E
SCHEMBL16539867 0.81 GAA (0.55) CA12CA1CA2CA3CA4
SCHEMBL2854043 0.81 CA1 (0.50) CA12CA1CA2CA3CA4
SCHEMBL14565682 0.79 CYP3A4 (0.34) CA1CA2CA9CYP3A4ALDH1A1
SCHEMBL6437742 0.79 CA1 (0.53) CA12CA1CA2CA3CA4
SCHEMBL144288 0.78 GAA (0.53) ALDH1A1TSHRCASP1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104854087-B Indole carboxamide derivatives as P2X receptor antagonists 埃科特莱茵药品有限公司 2017-03-22 CN disclosed
CN-104854087-A As P2X7Indole carboxamide derivatives of receptor antagonists ACTELION PHARMACEUTICALS LTD 2015-08-19 CN disclosed
WO-2013167633-A1 ACRYLAMIDE COMPOUNDS FOR COMBATING INVERTEBRATE PESTS BASF SE (DE) 2013-11-14 WO disclosed
WO-2008079105-A1 METHODS TO SYNTHESIZE INDOLES AS PRECURSORS FOR PHARMACEUTICALS SCIOS INC. (US) 2008-07-03 WO disclosed
WO-2008079105-A1 METHODS TO SYNTHESIZE INDOLES AS PRECURSORS FOR PHARMACEUTICALS SCIOS INC. (US) 2008-07-03 WO disclosed
US-20070066833-A1 Methods to synthesize indoles as precursors for pharmaceuticals SCIOS, INC. (US) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066833-A1 Methods to synthesize indoles as precursors for pharmaceuticals IDO1, IDO2, INMT CA12 2550/4885CA1 2887/4885CA2 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.